RNA (aviditybiosciences.com) Company Profit

Corporate emblem and logo of Avidity Biosciences Inc (RNA)

Avidity Biosciences (RNA) relies on competent management and research transparency. However, drug toxicity risks and share issuances are creating pressure on capital. Breakthrough developments in AOC conjugates are driving R&D growth. The company's profit trajectory reflects a market consensus on efficiency, with the indicator holding at 0.00, which helps investors avoid emotional decisions during corrections.

RNA Avidity Biosciences Inc Net Income (07/04/2022 - 10/29/2026)

Comprehensive metric breakdowns and analytics for Avidity Biosciences, Inc. (RNA)

- current quotes and average value forecast:
Market Chart Avidity Corp|RNA - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Avidity Corp|RNA - Enterprise Value
- book capitalization information:
Net Assets per Share Avidity Biosciences|RNA - Company Net Assets|Market Cap to Book Value Multiple aviditybiosciences.com|RNA - Cumulative Company Assets
- debt burden and liquidity indicators:
Debt to Capital Avidity Biosciences|RNA - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Avidity Biosciences Inc|RNA - Company Aggregate Debts|Debt to Book Capitalization Ratio Avidity Corp|RNA - Company Long-Term Debts|Short-Term Debt Volume Avidity Biosciences|Immediate Liquidity aviditybiosciences.com
- earnings and multiples data:
RNA - Company Net Income
Fundamental valuation:Avidity Corp, RNA
Signature product of Avidity Biosciences Inc

Fundamental asset selection requires an analysis of net income dynamics to assess the real operational efficiency of a business. This indicator reflects the daily market consensus on earnings, which for Avidity Biosciences (RNA), operating within a protected US perimeter without sanction risks, allows the company's financial results to filter out volatility and focus on the sustainability of RNA therapy development.

Direct competitors

TEM - Net Financial Result|QGEN (Qiagen N.V.) - Net Profit|Company Profit IONS (ionispharma.com)|Net Profit RGEN|Net Financial Result CRISPR Therapeutics Inc|Sema4 - Net Income|Profit After Payment of Taxes RARE (Ultragenyx Corp)|BEAM: Net Income|Company Net Income sarepta.com|TWST (Twist Bioscience, Inc.) - Net Income|10x Genomics Inc - Final Profit|NTLA (Intellia) - Net Profit|Company Net Income STOK|Net Profit BLFS|Net Financial Result wavelifesciences.com|Company Net Income Maze Therapeutics MAZE|Sionna Therapeutics, Inc. (SION) - Company Net Income|PRME - Company Net Income|Net Financial Result Taysha Corp TSHA|QURE: Net Profit|Net Income meiragtx.com|RGNX (REGENXBIO) - Net Profit|Solid Biosciences Inc (SLDB) - Net Financial Result|Net Profit OCGN|PACB - Company Net Income|Company Net Income Benitec Biopharma Inc. BNTC|DSGN: Company Profit|Rocket Pharmaceuticals, Inc. - Net Profit|4DMT (FDMT) - Net Income|LXEO: Net Profit|Company Net Income Korro Bio (KRRO)|Company Net Income Editas Medicine, Inc.|silence-therapeutics.com (SLN) - Net Financial Result|Company Net Income ProQR Therapeutics N.V. (PRQR)|CDXS (codexis.com) - Final Profit|Company Net Income Sangamo SGMO|NAUT: Company Profit|Metagenomi, Inc. - Net Profit|DTIL - Net Profit|GBIO: Net Profit|Company Profit BOLD|Company Net Income Exicure Inc.|Company Profit IMNN (Celsion Corporation)|Net Profit PHIO|Net Profit mustangbio.com (MBIO)|Net Profit RNAZ (TransCode Therapeutics, Inc.)|Net Profit Bionano Genomics Inc. BNGO|APDN: Net Income|BLUE: Company Net Income|IPA: Net Profit|OMGA - Net Financial Result|OMIC (Singular Genomics) - Net Profit|Company Profit RGLS (Regulus Therapeutics, Inc.)|Net Profit SYRS|Net Financial Result Telesis Bio, Inc|TRACON Pharmaceuticals - Net Income|Profit After Payment of Taxes UBX (unitybiotechnology.com)